CN1169578C - Beaver thymosin injection and its prepn - Google Patents

Beaver thymosin injection and its prepn Download PDF

Info

Publication number
CN1169578C
CN1169578C CNB011068019A CN01106801A CN1169578C CN 1169578 C CN1169578 C CN 1169578C CN B011068019 A CNB011068019 A CN B011068019A CN 01106801 A CN01106801 A CN 01106801A CN 1169578 C CN1169578 C CN 1169578C
Authority
CN
China
Prior art keywords
thymosin
thymus
acetone
otter
castor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011068019A
Other languages
Chinese (zh)
Other versions
CN1362262A (en
Inventor
康梦松
郭赛容
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB011068019A priority Critical patent/CN1169578C/en
Publication of CN1362262A publication Critical patent/CN1362262A/en
Application granted granted Critical
Publication of CN1169578C publication Critical patent/CN1169578C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a medical beaver thymosin injection which belongs to the technical field of medical products containing the thymus from feeding animals. The medical beaver thymosin injection is prepared by extracting a polypeptide material from the thymus of a beaver, the thymosin dialysate has high activity, the molecular weight is smaller than 10000, and the molecular weight of a main component is smaller than 6000. The content of a thymosin polypeptide is from 7 to 10 milligrams / milliliter, the mean value of the E-rosette activity determination is from 25 to 28%, and the yield coefficient is from 7 to 10 grams of thymosin / kilogram. The preparation method comprises: thymus extraction, homogenization, heating, foreign protein elimination, propanone deposition, sectional salting out, desalinization, drying, ultrafiltration and preparation.

Description

Castor otter medicine thymosin injection and manufacture method thereof
The invention belongs to the medical supplies technical field that contains from the nurture animal thymus, relate to a kind of castor otter medicine thymosin injection.
It is the cluster polypeptides matter that the nurture animal thymus produces that thymosin has another name called thymosin, has control and regulates the effect that animal immune reacts, and has been used to treat immunodeficiency and panimmunity dysfunction disease at present.The raw material of extraction thymosin commonly used is calf thymus and piglet thymus, because raw material is limited, causes cost high, makes thymosin become well sold and in short supply medicine in the clinical practice.1993 9 railway platforms of Chinese invention patent communique disclosed one piece " preparation method of human placental thymosin " on the 22nd, and (publication number: CN1076361A) patent application, the method for preparing thymosin with the thymic tissue of the normal fetus at 5-8 monthly age has been introduced in this patent application.Adopt this kind method to prepare thymosin obviously, its raw material sources are more limited, and its manufacturing cost is higher, and it is applied is very difficult.The main component of the thymic extract of general mammal such as cattle, pig etc. is thymic hyperplasia element, thymosin, thymic humoral factor, serum thymic factor, LS element.But these thymosin molecular weight that extract are big, active low, and result of use is poor.
The objective of the invention is to provide a kind of active height of injection with aboundresources, preparation, avirulence, clinical practice medical thymosin injection of castor otter and manufacture method thereof safely and effectively.
The castor otter has another name called coypu, castor, beaver, is herbvore nurture animal.The easy artificial cultivation of castor otter, the breeding potential height, the artificial cultivation cost is low, and at present, in all parts of the country all have a large amount of artificial cultivation as Shandong Province, Heilongjiang Province, Hebei province, Hunan Province and other places, is mainly used in meat.Therefore, extract thymosin with castor otter thymus, resource is very abundant.
The objective of the invention is to realize with the following methods.Castor otter medicine thymosin injection is the cluster polypeptides matter that extracts from castor otter thymus, its thymosin dialysate is active high, its molecular weight is less than 10000, and main component thymic hyperplasia element, thymosin, thymic humoral factor, serum thymic factor, the plain molecular weight of LS are less than 6000.This injection thymosin content of peptides 7-10 mg/ml, determination of activity E-rosette meansigma methods 25-28%, yield 7-10 restrains thymosin/kilogram.
The method that the present invention makes castor otter medicine thymosin injection comprises following technical process:
1, extract thymus: the castor otter after slaughtering is extracted fresh thymus on one's body,
2, homogenate: fresh thymus is removed fat, is cut into fragment and places in the high-speed tissue mashing machine, add 2-4 by per kilogram thymus and rise normal saline, smash to pieces and made into homogenate in 3-7 minute, the centrifugal 2000-4000 of refrigerated centrifuger rev/min, 7-13 minute extracting solution,
3, heating foreigh protein removing: extracting solution is heated to 80-90 ℃ rapidly in water-bath, kept 12-18 minute, be cooled to rapidly below 10 ℃, the centrifugal precipitation of removing is collected clear liquid,
4, acetone precipitation: clear liquid is chilled to 4 ℃, add 4-6 times of volume-8--12 ℃ acetone placed 3-5 hour in-8--12 ℃, filtered collecting precipitation, vacuum drying gets acetone powder,
5, segmentation is saltoutd: acetone powder is dissolved in the PH6.8-7.2 phosphate buffer, make every milliliter to contain protein 23-28 milligram, the saturated ammonium sulfate solution that adds PH6.8-7.2 makes and reaches the 23-28% saturation, the centrifugal precipitation of removing, supernatant is transferred PH3.8-4.2, add ammonium sulfate and make saturation reach 48-52%, the centrifugal collection thing of saltouing
6, desalination, drying: the thing of saltouing is with the recrystallization desalination repeatedly of cold aqueous acetone, and after checking no sulfate, cold acetone is washed 1-3 time, and cold diethyl ether is washed 1-3 time, drain, and vacuum drying,
7, ultrafiltration: desalination dry powder is dissolved in normal saline and transfers the PH7.0-7.5 ultrafiltration, get ultrafiltrate,
8, preparation: in ampoule bottle, sealing by fusing gets required finished product with the ultrafiltrate sterile filling.
Manufacture method of the present invention is simple to operate, is suitable for producing in enormous quantities, adopts heating Deproteinization operation to make protein coagulation more complete, is easy to remove; Utilize the cold acetone that contains that the thing of saltouing is carried out the recrystallization desalination, shorten the time greatly, reduced opportunities for contamination.Thereby the castor otter medicine thymosin injection made from the inventive method is active high, avirulence, and no thermal source, clinical practice is safe and effective.
Be indefiniteness embodiment of the present invention below:
Castor otter after slaughtering is extracted fresh thymus on one's body, fresh thymus is removed fat, being cut into fragment places in the high-speed tissue mashing machine, add 3 liters of normal saline by per kilogram thymus, smash to pieces and made into homogenate in 5 minutes, centrifugal 3000 rev/mins of refrigerated centrifuger, got extracting solution in 10 minutes, extracting solution is heated to 85 ℃ rapidly in water-bath, kept 15 minutes, be cooled to rapidly below 10 ℃, the centrifugal precipitation of removing is collected clear liquid, and clear liquid is chilled to 4 ℃,-10 ℃ of acetone that add 5 times of volumes were placed 4 hours in-10 ℃, filter collecting precipitation, vacuum drying gets acetone powder, and acetone powder is dissolved in the PH7.0 phosphate buffer, make every milliliter to contain 25 milligrams in protein, the saturated ammonium sulfate solution that adds PH7.0 makes and reaches 25% saturation, the centrifugal precipitation of removing, and supernatant is transferred PH4.0, adding ammonium sulfate makes saturation reach 50%, the centrifugal collection thing of saltouing, the thing of saltouing is with the recrystallization desalination repeatedly of cold aqueous acetone, after checking no sulfate, cold acetone is washed 2 times, cold diethyl ether is washed 2 times, drains vacuum drying, desalination dry powder is dissolved in normal saline and transfers the PH7.2 ultrafiltration, get ultrafiltrate, in 2 milliliters of ampoule bottles, sealing by fusing gets required castor otter medicine thymosin injection finished product with the ultrafiltrate sterile filling.
The castor otter medicine thymosin injection that makes with the present invention test 25 patients clinicals, to intramuscular injection of different sick kind or subcutaneous injection 5-10 milliliters, and weekly twice, rheumatoid arthritis effective percentage 79%, myasthenia gravis are 75%.To chronic hepatitis B patient, the next day 1 injection, 10 milligrams of per injections continue existing two months, liver function recovery is normal, common sympton disappears, to the total effective rate of viral hepatitis more than 80%.

Claims (3)

1, a kind of castor otter medicine thymosin injection, it is characterized in that it being the cluster polypeptides matter that extracts from castor otter thymus, its thymosin dialysate is active high, its molecular weight is less than 10000, main component thymic hyperplasia element, thymosin, thymic humoral factor, serum thymic factor, the plain molecular weight of LS are less than 6000, and it is the medical thymosin injection that makes by the following method:
(1) extract thymus: the castor otter after slaughtering is extracted fresh thymus on one's body,
(2) homogenate: fresh thymus is removed fat, is cut into fragment and places in the high-speed tissue mashing machine, add 2-4 by per kilogram thymus and rise normal saline, smash to pieces and made into homogenate in 3-7 minute, the centrifugal 2000-4000 of refrigerated centrifuger rev/min, 7-13 minute extracting solution,
(3) heating foreigh protein removing: extracting solution is heated to 80-90 ℃ rapidly in water-bath, kept 12-18 minute, be cooled to rapidly below 10 ℃, the centrifugal precipitation of removing is collected clear liquid,
(4) acetone precipitation: clear liquid is chilled to 4 ℃, add 4-6 times of volume-8--12 ℃ acetone placed 3-5 hour in-8--12 ℃, filtered collecting precipitation, vacuum drying gets acetone powder,
(5) segmentation is saltoutd: acetone powder is dissolved in the PH6.8-7.2 phosphate buffer, make every milliliter to contain protein 23-28 milligram, the saturated ammonium sulfate solution that adds PH6.8-7.2 makes and reaches the 23-28% saturation, the centrifugal precipitation of removing, supernatant is transferred PH3.8-4.2, add ammonium sulfate and make saturation reach 48-52%, the centrifugal collection thing of saltouing
(6) desalination, drying: the thing of saltouing is with the recrystallization desalination repeatedly of cold aqueous acetone, and after checking no sulfate, cold acetone is washed 1-3 time, and cold diethyl ether is washed 1-3 time, drain, and vacuum drying,
(7) ultrafiltration: desalination dry powder is dissolved in normal saline and transfers the PH7.0-7.5 ultrafiltration, get ultrafiltrate,
(8) preparation: the ultrafiltrate sterile filling is got required finished product.
2, castor otter medicine thymosin injection according to claim 1 is characterized in that this injection thymosin content of peptides 7-10 mg/ml, determination of activity E-rosette meansigma methods 25-28%, and yield 7-10 restrains thymosin/kilogram.
3, a kind of method of making the described castor otter medicine of claim 1 thymosin injection comprises following technical process:
(1) get thymus: the castor otter after slaughtering is extracted fresh thymus on one's body,
(2) homogenate: fresh thymus is removed fat, is cut into fragment and places in the high-speed tissue mashing machine, add 2-4 by per kilogram thymus and rise normal saline, smash to pieces and made into homogenate in 3-7 minute, the centrifugal 2000-4000 of refrigerated centrifuger rev/min, 7-13 minute extracting solution,
(3) heating foreigh protein removing: extracting solution is heated to 80-90 ℃ rapidly in water-bath, kept 12-18 minute, be cooled to rapidly below 10 ℃, the centrifugal precipitation of removing is collected clear liquid,
(4) acetone precipitation: clear liquid is chilled to 4 ℃, add 4-6 times of volume-8--12 ℃ acetone placed 3-5 hour in-8--12 ℃, filtered collecting precipitation, vacuum drying gets acetone powder,
(5) segmentation is saltoutd: acetone powder is dissolved in the PH6.8-7.2 phosphate buffer, make every milliliter to contain protein 23-28 milligram, the saturated ammonium sulfate solution that adds PH6.8-7.2 makes and reaches the 23-28% saturation, the centrifugal precipitation of removing, supernatant is transferred PH3.8-4.2, add ammonium sulfate and make saturation reach 48-52%, the centrifugal collection thing of saltouing
(6) desalination, drying: the thing of saltouing is with the recrystallization desalination repeatedly of cold aqueous acetone, and after checking no sulfate, cold acetone is washed 1-3 time, and cold diethyl ether is washed 1-3 time, drain, and vacuum drying,
(7) ultrafiltration: desalination dry powder is dissolved in normal saline and transfers the PH7.0-7.5 ultrafiltration, get ultrafiltrate,
(8) preparation: in ampoule bottle, sealing by fusing gets required finished product with the ultrafiltrate sterile filling.
CNB011068019A 2001-01-03 2001-01-03 Beaver thymosin injection and its prepn Expired - Fee Related CN1169578C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB011068019A CN1169578C (en) 2001-01-03 2001-01-03 Beaver thymosin injection and its prepn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB011068019A CN1169578C (en) 2001-01-03 2001-01-03 Beaver thymosin injection and its prepn

Publications (2)

Publication Number Publication Date
CN1362262A CN1362262A (en) 2002-08-07
CN1169578C true CN1169578C (en) 2004-10-06

Family

ID=4655771

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011068019A Expired - Fee Related CN1169578C (en) 2001-01-03 2001-01-03 Beaver thymosin injection and its prepn

Country Status (1)

Country Link
CN (1) CN1169578C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109627282B (en) * 2018-11-12 2023-06-30 吉林大学 Deer placenta active protein, and extraction method and application thereof
CN112707888A (en) * 2021-02-03 2021-04-27 上海雅本化学有限公司 Synthesis method of N-2-pyridyl 5-pyrimidyl methylamine

Also Published As

Publication number Publication date
CN1362262A (en) 2002-08-07

Similar Documents

Publication Publication Date Title
Baxter et al. Nephrotoxic Serum Nephritis in Rats: I. Distribution and Specificity of the Antigen Responsible for the Production of Nephrotoxic Antibodies
CN104926937A (en) Method for extracting hirudin from leech saliva
CN101628025B (en) Pharmaceutical composition containing deer bone extractive and melon seed extract
CN100446779C (en) Method for preparing acanthopanax senticousus extracting liquid/extraction
CN102232970A (en) Cell injection for treating bone injury and preparation method thereof
CN101647822A (en) Bionic enzymatic hydrolysate for ground beeltle and application thereof
CN110420325A (en) Refined polyvalent anti-snake poison lyophilized blood serum and preparation method thereof
CN101134050A (en) Pharmaceutical composition for reinforcing organism immunity and technique of preparing the same
CN100509843C (en) Acid-modified arabinogalactan protein composition
CN1169578C (en) Beaver thymosin injection and its prepn
CN105777921A (en) Astragalus polysaccharide extraction process and application thereof
CN1030528C (en) Human placental Collagen and the prepn. thereof
CN104161207B (en) The feed additive of a kind of anti-duck bacterial disease, preparation method and application
CN103611023A (en) Preparation method of transfer factor
CN1179979C (en) Hematopoietic arabinogalactan composition
CN101721427A (en) Method for preparing gallinaceous Newcastle disease transspecific factor
CN109966318A (en) A kind of placental peptide injection preparation method
CN100391474C (en) Injection medicine for treating platelet abatement
CN107126555A (en) A kind of pigskin collagen small peptide active component composition of wound healing
CN103041366B (en) Bone peptide composition and preparation method thereof
CN107929351B (en) Preparation process of Aidi injection preparation
CN110898080B (en) Application of horseshoe crab plasma in promoting growth and development
CN114712481B (en) Composite plant source polypeptide and preparation method and application thereof
CN113995791B (en) Gynura procumbens compound medicine capable of benefiting qi, nourishing blood, and preventing and treating anemia and preparation method and application thereof
CN107006653A (en) A kind of blue flower seedling three in west steeps the production method of platform tea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee